REVELATION BIOSCIENCES, INC.
REVB evidence brief
What we can confirm
- BioSniper Score:
- 6.3 / 10
- Market Cap:
- $4.0M
- Lead Asset:
- gemini (Phase 2)
What it means
What to watch
Prepared research question
What matters most for REVB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · REVB
Revelation Biosciences is a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, with a lead candidate Gemini in Phase 1b for chronic kidney disease and a cash position of $11.5M as of June 30, 2026.
Key risk: Limited cash runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$4.0M
Cash Runway
—
Lead Asset
gemini (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 1 clinical trial for REVELATION BIOSCIENCES, INC..
Revelation Biosciences is a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, with a lead candidate Gemini in Phase 1b for chronic kidney disease and a cash position of $11.5M as of June 30, 2026.
- Clinical-stage life sciences company focused on rebalancing inflammation to optimize health [news · 2025-07-16].
- Completed dosing of patients in the PRIME Phase 1b clinical study of Gemini in Stage 3 and 4 Chronic Kidney Disease as of July 2025 [news · 2025-07-16].
- Cash and cash equivalents of $11.5 million as of June 30, 2026 [sec_mda · as of 2026-08-06].
- Net income of -$3.3 million for the period ended June 30, 2026 [latest reported financials].
- Accumulated deficit of $55.8 million as of June 30, 2026 [sec_mda · as of 2026-08-06].
What works
- Completed dosing in a Phase 1b study (PRIME) for its lead candidate Gemini in chronic kidney disease, indicating clinical progress [news · 2025-07-16].
- Raised net proceeds of $75.9 million from equity and warrant issuances since inception, providing a funding base [sec_mda · as of 2026-08-06].
What to weigh
- Cash and cash equivalents of $11.5 million as of June 30, 2026, which may limit runway given plans to substantially increase R&D expenses [sec_mda · as of 2026-08-06].
- Accumulated deficit of $55.8 million as of June 30, 2026, reflecting sustained operating losses [sec_mda · as of 2026-08-06].
- Net loss of $3.3 million for the period ended June 30, 2026, indicating ongoing negative cash flow [latest reported financials].
From the filings
Quoted directly from source documents.
Cash and cash equivalents as of June 30, 2026
“As of June 30, 2026, we had available cash and cash equivalents of $11.5 million”
SEC MD&A · August 6, 2026
Accumulated deficit as of June 30, 2026
“accumulated deficit of $55.8 million”
SEC MD&A · August 6, 2026
Net proceeds raised from equity and warrants
“we have funded our operations from the issuance and sale of our common stock, preferred stock and warrants, from which we have raised net proceeds of $75.9 million”
SEC MD&A · August 6, 2026
Risks & what to watch (3)›
Key risks
- Limited cash runway — Cash of $11.5M as of June 30, 2026 may be insufficient to fund planned R&D increases without additional financing [sec_mda · as of 2026-08-06].
- No approved products or revenue — Company is clinical-stage with no marketed products; all candidates are in development, creating binary outcome risk [sec_mda · as of 2026-08-06].
- Accumulated operating losses — Accumulated deficit of $55.8M as of June 30, 2026 reflects sustained net losses with no near-term profitability [sec_mda · as of 2026-08-06].
What to watch
- Results from the PRIME Phase 1b study of Gemini in CKD, which completed dosing in July 2025 [news · 2025-07-16].
- Cash runway and potential need for additional capital raises given $11.5M cash and plans to increase R&D spending [sec_mda · as of 2026-08-06].
- Progress of other pipeline candidates (REVTx-200, REVTx-99b) which remain in early development [sec_mda · as of 2023-11-09].
Sources: News · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run REVELATION BIOSCIENCES, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available REVELATION BIOSCIENCES, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.24 · 0% dilution
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
11
Total value held
$600K
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 323,241 | $388K |
| sabby management, llc | 99,432 | $119K |
| geode capital management, llc | 43,195 | $52K |
| vanguard fiduciary trust co | 13,127 | $16K |
| xtx topco ltd | 11,385 | $14K |
| ubs group ag | 4,115 | $5K |
| tower research capital llc (trc) | 4,074 | $5K |
| royal bank of canada | 747 | $1K |
| sbi securities co., ltd. | 344 | $413 |
| bnp paribas asset management holding s.a. | 9 | $11 |
Showing top 10 of 11 institutional holders of REVELATION BIOSCIENCES, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 0.6%
- Days to cover
- 0.3
- Shares short
- 22,511
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
REVB short interestGovernance
Frequently asked questions
What is the AI investment thesis for REVELATION BIOSCIENCES, INC.?
Revelation Biosciences is a clinical-stage life sciences company focused on rebalancing inflammation to optimize health, with a lead candidate Gemini in Phase 1b for chronic kidney disease and a cash position of $11.5M as of June 30, 2026.
What is REVELATION BIOSCIENCES, INC.'s lead drug candidate?
REVELATION BIOSCIENCES, INC.'s most advanced tracked candidate is gemini (Phase 2) for Renal Insufficiency, Chronic.
Who is the CEO of REVELATION BIOSCIENCES, INC.?
Mr. James M. Rolke is the chief executive officer of REVELATION BIOSCIENCES, INC. (REVB).
Where is REVELATION BIOSCIENCES, INC. headquartered?
REVELATION BIOSCIENCES, INC. (REVB) is headquartered in San Diego, CA, United States.
What therapeutic areas does REVELATION BIOSCIENCES, INC. focus on?
REVELATION BIOSCIENCES, INC. develops therapies across Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.